Adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (6–10 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
1 finding from 1 review
Maintenance of clinical remission · people with Crohn's disease
Vedolizumab leads to higher maintenance of clinical remission (52–60 weeks) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (52–60 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).
1 finding from 1 review
Disease activity · people with inflammatory bowel disease
1 finding from 1 review
Flare‐ups or relapse (continuous) · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Flare‐ups/relapse (dichotomous; adults) · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · people with inflammatory bowel disease
1 finding from 1 review
Flare‐ups or relapse (continuous) · people with inflammatory bowel disease
1 finding from 1 review
Flare‐ups or relapse (4‐12 months) (dichotomous outcome) · people with inflammatory bowel disease
It is very uncertain whether patient education and standard care changes flare‐ups or relapse (4‐12 months) (dichotomous outcome) compared with standard care (very low certainty).
1 finding from 1 review
Quality of life (2 weeks‐12 months) · people with inflammatory bowel disease
1 finding from 1 review
Disease activity · people with inflammatory bowel disease
1 finding from 1 review
Flare‐ups or relapse (continuous) · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Flare‐ups/relapse (dichotomous; adults) · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IBDQ at week 8 · people with inflammatory bowel disease
1 finding from 1 review
Disease activity · people with inflammatory bowel disease
1 finding from 1 review
Resolution of rCDI · adults with recurrent Clostridioides difficile infection (rCDI)
Summary of findings table ‐ Fecal microbiota transplantation (FMT) probably leads to higher resolution of rCDI compared with control (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with recurrent Clostridioides difficile infection (rCDI)
Summary of findings table ‐ Fecal microbiota transplantation (FMT) showed no clear difference in serious adverse events compared with control (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with recurrent Clostridioides difficile infection (rCDI)
Summary of findings table ‐ Fecal microbiota transplantation (FMT) showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review